4D PrintingBiofabricationBioprintingMedical AM

Carl Zeiss Meditec and Precise Bio to develop fabricated corneal tissue

For transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Carl Zeiss Meditec, one of the world’s leading medical technology companies, and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.

Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio’s two cornea transplant products and has exclusive worldwide commercialization rights for these products. Financial terms were not disclosed.

Carl Zeiss Meditec and Precise Bio to develop fabricated corneal tissue. For transplants in patients that require endothelial keratoplasty.
Precise Bio’s bio-fabricated cornea

“This investment in Precise Bio is expected to complement our leading portfolio of cataract and corneal refractive workflow solutions,” said Euan S. Thomson, Ph.D., President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. “The technology has the potential to advance treatment options for corneal disease, as well as for elective procedures – furthering enabling optimization of patient care.”

“We are very excited with this partnership that builds on our successful, ongoing collaboration with ZEISS for the development of corneal tissues to address unmet needs in the field of ophthalmology,” said Aryeh Batt, Co-founder, and CEO of Precise Bio. “This strategic agreement leverages ZEISS’ global leadership in ophthalmology and Precise’s innovative and unique 4D bio-fabrication platform technology. We are confident that the synergy between the two companies will allow us to develop breakthrough solutions for recovering patients’ eyesight, bringing hope to hundreds of millions of patients worldwide.”

Precise Bio combines engineering, biomaterials, cell technology, bioengineering, and 3D printing into a 4D bio-fabrication platform for transplantable organs and tissues. The company’s proprietary platform technology allows to fabricate tissues by ‘printing’ cells in a single-cell resolution and spatial accuracy, enabling complex organoid constructs with both structural integrity and long-term cell viability. Overcoming multiple technology challenges, Precise Bio’s 4D bio-fabrication technology allows to reliably scale up tissue engineering for clinical use, and produce large quantities in a reproducible, quality-controlled, and cost-effective process. Precise Bio’s ophthalmological pipeline consists of three products – the two cornea products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which demonstrated successful results in animal models.

Bio-fabricated tissues comprised of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue in cases where there is a lack of tissue, or solve unmet therapeutic needs.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.